Muhammad Saghir Khan
Overview
Explore the profile of Muhammad Saghir Khan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atwiine B, Chagaluka G, Chimalizeni Y, Khan M, Chantada G, Israels T, et al.
Pediatr Blood Cancer
. 2024 Oct;
72(1):e31364.
PMID: 39375879
No abstract available.
2.
Mushtaq N, Qureshi B, Javed G, Sheikh N, Bakhshi S, Ali Laghari A, et al.
Front Oncol
. 2024 Mar;
14:1325167.
PMID: 38487721
Introduction: Initiated in June 2019, this collaborative effort involved 15 public and private sector hospitals in Pakistan. The primary objective was to enhance the capacity for pediatric neuro-oncology (PNO) care,...
3.
Khan M, Maaz A, Qazi A, Aslam S, Riaz S, Malik A, et al.
Pediatr Blood Cancer
. 2023 Nov;
71(2):e30760.
PMID: 37962283
Introduction: The objectives of this study were to evaluate the prognostic impact of pre-referral surgical resection of Wilms tumor (WT) performed at non-oncology centers, and to strategize an improved care...
4.
Schneider N, Rossell N, Khan M
Psychooncology
. 2023 Oct;
32(11):1710-1717.
PMID: 37795966
Objectives: While pediatric cancer survival rates have improved in high-income countries, they remain much lower in low- and middle-income countries (L/MICs). While much focus in recent years has been on...
5.
Li C, Kurkure P, Arora R, Chen B, Kirgizov K, Okamoto Y, et al.
JCO Glob Oncol
. 2023 Sep;
9:e2300153.
PMID: 37656946
In Asia, a few countries have a long and established history of collaborative clinical trials successfully formed national children's cancer study groups, but many still do not have such groups....
6.
Moreira D, Metzger M, Antillon-Klussmann F, Gonzalez-Ramella O, Gao Y, Bazzeh F, et al.
Cancer
. 2023 Jul;
129(21):3448-3456.
PMID: 37417913
Purpose: In the absence of a standardized tool to assess the quality of pediatric hematology/oncology training programs, the Education Program Assessment Tool (EPAT) was conceptualized as a user-friendly and adaptable...
7.
Shaheen N, Jan M, Riaz S, Khan M
J Cancer Allied Spec
. 2023 May;
6(2):e351.
PMID: 37197606
Background: Long-term survivors of childhood malignancies are at increased risk of experiencing treatment-related morbidities. Survival into late adulthood in these children provides ample time for the acquisition of long-term sequelae....
8.
Denburg A, Fundytus A, Khan M, Howard S, Antillon-Klussmann F, Sengar M, et al.
JCO Glob Oncol
. 2022 Jun;
8:e2200034.
PMID: 35749676
Purpose: Access to essential cancer medicines is a major determinant of childhood cancer outcomes globally. The degree to which pediatric oncologists deem medicines listed on WHO's Model List of Essential...
9.
Pritchard-Jones K, Challinor J, Hunger S, Sung L, Davidson A, Morrissey L, et al.
Pediatr Blood Cancer
. 2022 Feb;
69(6):e29577.
PMID: 35166434
No abstract available.
10.
Major A, Palese M, Ermis E, James A, Villarroel M, Klussmann F, et al.
JCO Glob Oncol
. 2022 Feb;
8:e2100266.
PMID: 35157510
Purpose: The global pediatric oncology clinical research landscape, particularly in Central and South America, Africa, and Asia, which bear the highest burden of global childhood cancer cases, is less characterized...